AGP Executive Report
Last update: 9 hours agoRare Cancer Deal: Swedish Sobi is paying $75m upfront (up to $580m total) to license Innate Pharma’s lacutamab for cutaneous T-cell lymphoma, with a Phase 3 TELLOMAK-3 push aimed at accelerated approval in Sézary syndrome. Drug Manufacturing Push: Global drugmakers including Pfizer, AstraZeneca, Roche and Eli Lilly are pledging hundreds of billions in U.S. investments to expand manufacturing and R&D. Reproductive Health Access: In Liberia, donor funding gaps are causing contraceptive stockouts, leaving girls like Beatrice without Depo-Provera and raising fears of unsafe abortions. Health & Safety in Heat: Europe’s record heatwaves are linked to rising heat-related health problems and excess deaths, with guidance focused on practical ways to cope. Sports Injury Watch (Sweden-linked): Barcelona’s Swedish winger Roony Bardghji is awaiting knee test results after a possible ACL injury, a setback that could sideline him for months. Sweden Tobacco Trend: A new look at smoking declines highlights Sweden’s low smoking rates, driven by snus and nicotine pouches.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[M&A Roundup: Novo Nordisk Enters AI Drug Discovery Partnership with Amazon, Innate Pharma Partners with Sobi, Innovent Enters Commercialization Agreement with Daiichi Sankyo]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27408038-933135974-0bdf67f64b798bbbc3de98ccd7328942d30a69b9-1280x720-200x113.png)
